Does the CYP3A5 3 polymorphism affect in vivo drug elimination?

Pharmacogenetics

Volumn 13, Issue 10, 2003, Pages 585-587

  Thummel, Kenneth E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ERYTHROMYCIN; FLUCONAZOLE; KETOCONAZOLE; MIDAZOLAM; RIFAMPICIN; ANXIOLYTIC AGENT; CYP3A PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450;

ALLELE; CYTOKINE RELEASE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HOMOZYGOSITY; HUMAN; IN VIVO STUDY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; SHORT SURVEY; WILD TYPE; GENETICS; GENOTYPE; METABOLIC CLEARANCE RATE; NOTE; PHENOTYPE;

STAPHYLOCOCCUS PHAGE 3A;

ANTI-ANXIETY AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; METABOLIC CLEARANCE RATE; MIDAZOLAM; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 0142157748     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200310000-00001     Document Type: Short Survey

References (17)

1. Daly AK. Molecular basis of polymorphic drug metabolism. J Mol Med 1995; 73:539-553.
2. Guengerich FP. Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 1997; 43:7-35.
3. Wrighton SA, Thummel KE. CYP3A. In: Levy RH, Trager WF, Thummel KE, Hansten PD, Eichelbaum M (editors): Metabolic Drug Interactions. New York: Lippincott-Raven; 2000, pp. 115-133.
4. Gibson GG, Plant NJ, Swales KE, Ayrton A, El-Sankary W. Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 2002; 32:165-206.
5. Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10:373-388.
6. Finta C, Zaphiropoulos PG. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 2000; 260: 13-23.
7. Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M, et al. Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 2001; 281:1349-1355.
8. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver - evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997; 247:625-634.
9. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, et al. Coregulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62:162-172.
10. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54:1271-1294.
11. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-391.
12. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11:773-779.
13. Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Dobrinska MR, et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 2001; 11:781-791.
14. Shih PS, Huang JD. Pharmacokinetics of midazolam and 1′- hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 2002; 30:1491-1496.
15. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20:3683-3690.
16. Rekka E, Evdokimova E, Eeckhoudt S, Labar G, Calderon PB. Role of temperature on protein and mRNA cytochrome P450 3A (CYP3A) isozymes expression and midazolam oxidation by cultured rat precision-cut liver slices. Biochem Pharmacol 2002; 64:633-643.
17. Gibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 1999; 27:180-187.